<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(5)</volume><submitter>Jia-Yong S</submitter><pubmed_abstract>&lt;h4>Background and aim&lt;/h4>Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening complication, and patients who experience it are formally assigned to stage T4 in the TNM system, while many clinicians informally assign them to stage C in the more widely used Barcelona Clinic Liver Cancer (BCLC) system. The present study explored whether these re-staging practices are appropriate for HCC patients who suffer tumor rupture.&lt;h4>Methods&lt;/h4>We retrospectively reviewed the records of 1952 HCC patients who underwent hepatic resection at our hospital between January 2017 and June 2021. We compared recurrence-free and overall survival between 143 patients who had BCLC stage A or B disease at the time of spontaneous rupture and 449 patients who had BCLC stage C disease without rupture.&lt;h4>Results&lt;/h4>Overall survival rate was significantly higher among the 143 patients (1, 3, 5-year survival rate was 80.3%, 60.4%, 51.4%) with rupture than among the 449 (1, 3, 5-year survival rate was 69.5%, 41.5%, 32.4%) with BCLC stage C disease (hazard ratio 1.65, 95% confidence interval 1.29 to 2.12). The two groups had similar recurrence-free survival (hazard ratio 1.19, 95% confidence interval 0.92 to 1.53), but most patients with rupture were able to receive interventional and potentially curative treatments after recurrence, whereas most patients in BCLC stage C received interventional or supportive care. Similar results were obtained after propensity score matching.&lt;h4>Conclusion&lt;/h4>HCC patients who experience spontaneous rupture tumor while in BCLC stage A or B have better prognosis than patients in BCLC stage C without rupture. Our results suggest that HCC patients who suffer rupture in BCLC stage A or B should not be assigned to BCLC stage C.</pubmed_abstract><journal>Heliyon</journal><pagination>e27355</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10915404</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comparison of post-resection survival between hepatocellular carcinoma patients in BCLC stage A or B who experience tumor rupture and patients in BCLC stage C who do not.</pubmed_title><pmcid>PMC10915404</pmcid><pubmed_authors>Jian-Hong Z</pubmed_authors><pubmed_authors>Jun-Shao T</pubmed_authors><pubmed_authors>Rong-Wei X</pubmed_authors><pubmed_authors>Wei T</pubmed_authors><pubmed_authors>Ding-Wen L</pubmed_authors><pubmed_authors>Jia-Yong S</pubmed_authors><pubmed_authors>Qing-Qing C</pubmed_authors><pubmed_authors>Mei C</pubmed_authors><pubmed_authors>Hong-Liang W</pubmed_authors><pubmed_authors>Liang M</pubmed_authors><pubmed_authors>Yu-Tong C</pubmed_authors><pubmed_authors>Ping-Ping G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of post-resection survival between hepatocellular carcinoma patients in BCLC stage A or B who experience tumor rupture and patients in BCLC stage C who do not.</name><description>&lt;h4>Background and aim&lt;/h4>Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening complication, and patients who experience it are formally assigned to stage T4 in the TNM system, while many clinicians informally assign them to stage C in the more widely used Barcelona Clinic Liver Cancer (BCLC) system. The present study explored whether these re-staging practices are appropriate for HCC patients who suffer tumor rupture.&lt;h4>Methods&lt;/h4>We retrospectively reviewed the records of 1952 HCC patients who underwent hepatic resection at our hospital between January 2017 and June 2021. We compared recurrence-free and overall survival between 143 patients who had BCLC stage A or B disease at the time of spontaneous rupture and 449 patients who had BCLC stage C disease without rupture.&lt;h4>Results&lt;/h4>Overall survival rate was significantly higher among the 143 patients (1, 3, 5-year survival rate was 80.3%, 60.4%, 51.4%) with rupture than among the 449 (1, 3, 5-year survival rate was 69.5%, 41.5%, 32.4%) with BCLC stage C disease (hazard ratio 1.65, 95% confidence interval 1.29 to 2.12). The two groups had similar recurrence-free survival (hazard ratio 1.19, 95% confidence interval 0.92 to 1.53), but most patients with rupture were able to receive interventional and potentially curative treatments after recurrence, whereas most patients in BCLC stage C received interventional or supportive care. Similar results were obtained after propensity score matching.&lt;h4>Conclusion&lt;/h4>HCC patients who experience spontaneous rupture tumor while in BCLC stage A or B have better prognosis than patients in BCLC stage C without rupture. Our results suggest that HCC patients who suffer rupture in BCLC stage A or B should not be assigned to BCLC stage C.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-15T06:36:52.098Z</modification><creation>2026-06-15T03:09:09.869Z</creation></dates><accession>S-EPMC10915404</accession><cross_references><pubmed>38449598</pubmed><doi>10.1016/j.heliyon.2024.e27355</doi></cross_references></HashMap>